Jefferies Raises Revenue, EPS Estimates for Agilent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Jefferies today raised its EPS estimate for Agilent Technologies to $2.63 from $2.60, on the strength of recent organic order trends and anticipated minimal effects from the Japanese earthquake and tsunami.

The investment firm also increased the share-price target to $56 from $55 and revenue estimates for full-year 2011 to $6.39 billion from $6.35 billion. It has a "Buy" rating on Agilent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.